SACGT Induces Test Maker Sponsorship Of Follow-Up Trials, Taps Myriad
This article was originally published in The Gray Sheet
Executive Summary
The HHS Secretary's Advisory Committee on Genetic Testing plans to charge its data work group with investigating the department's role in providing incentives for manufacturers to continue follow-up studies where data is lacking on clinical utility and validity for commercialized tests
You may also be interested in...
BRCA1 patent infringement suit
Myriad Genetics assumes Oncormed's BRCA1/BRCA2 breast and ovarian genetic testing business and exclusive rights to Oncormed's current and pending patents for BRCA1/BRCA2 under terms of a patent infringement settlement jointly announced May 18. Oncormed will transfer to Myriad, for undisclosed fees, the components of its genetic testing business, including professional contacts and customer lists. Each company retains diagnostic and therapeutic rights in their respective patents. Oncormed initiated the suit in November, alleging that Myriad's BRACAnalysis genetic testing service infringed its BRCA1-related patent. Myriad then filed its own suit in December, claiming that Oncormed infringed a Myriad patent related to breast and ovarian cancer susceptibility genes ("The Gray Sheet" Dec. 8, 1997, In Brief)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.